Back to Search
Start Over
BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.
- Source :
-
Oncogene [Oncogene] 2022 Mar; Vol. 41 (10), pp. 1397-1409. Date of Electronic Publication: 2022 Jan 11. - Publication Year :
- 2022
-
Abstract
- Hepatocellular carcinoma (HCC) has emerged as the third cause of cancer-related death owing to lacking effective systemic therapies. Genomic DNA sequencing revealed the high frequency of loss-of-function mutations in ARID2, which encodes a subunit of SWI/SNF chromatin remodeling complex, however, the therapeutic strategy for the HCC patients with ARID2 mutations is still completely unclear. In this study, we first performed a high-throughput screening approach using a compound library consisting of 2 180 FDA-approved drugs and other compounds, to elicit the potential drugs for synthetic lethality to target ARID2-deficient HCC cells. Interestingly, JQ1, a selective inhibitor of bromodomain protein BRD4, uniquely suppressed the growth of ARID2- deficient HCC cells. Next JQ1 is further confirmed to predominantly induce cell lethality upon ARID2 depletion through exacerbating DNA damage, especially double strand breaks (DSBs). Functional assays demonstrated that both BRD4 inhibition and ARID2 deficiency synergistically impede two main DNA damage repair pathways, homologous recombination (HR) and non-homologous end-joining (NHEJ), through attenuating the transcription of BRCA1, RAD51, and 53BP1, which encode the core molecules responsible for DSB repair. Mechanistically, both ARID2 and BRD4 exert a synergistic effect for maintaining transcriptional enhancer-promoter loops of these genes within chromatin conformation. However, as both ARID2 and BRD4 are disrupted, the expression of these DNA repair-related genes in response to DNA damage are hindered, resulting in DSB accumulation and cell apoptosis. Taken together, this study discloses that BRD4 inhibition may induce synthetic lethality in ARID2-deficient HCC cells, which might provide a potential therapeutic strategy for HCC patients with ARID2 mutations.<br /> (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
- Subjects :
- Cell Cycle Proteins genetics
Cell Cycle Proteins metabolism
Cell Line, Tumor
DNA Damage
DNA End-Joining Repair
DNA Repair
Humans
Nuclear Proteins genetics
Nuclear Proteins metabolism
Synthetic Lethal Mutations
Transcription Factors genetics
Transcription Factors metabolism
Carcinoma, Hepatocellular drug therapy
Carcinoma, Hepatocellular genetics
Carcinoma, Hepatocellular metabolism
Liver Neoplasms drug therapy
Liver Neoplasms genetics
Liver Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1476-5594
- Volume :
- 41
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Oncogene
- Publication Type :
- Academic Journal
- Accession number :
- 35017665
- Full Text :
- https://doi.org/10.1038/s41388-022-02176-2